Streetbeat News

Stock Prices

CGEM

Cullinan Therapeutics reported updated results from its Phase 2b study of zipalertinib for non-small cell lung cancer at ESMO 2024. The study showed a 40% objective response rate and a manageable safety profile in patients with specific mutations. Enrollment for the trial was completed ahead of schedule.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 8:38 am

NVS

Novartis' Phase 3 NATALEE trial results show that adding Kisqali (Ribociclib) to endocrine therapy significantly reduces the risk of recurrence in certain early breast cancer patients by 28.5% beyond a three-year treatment period.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 8:33 am

NUVL

Nuvalent has reported positive Phase 1 data for its NSCLC programs, showing potential best-in-class profiles for zidesamtinib and NVL-655. The company is accelerating its development timeline, with pivotal data expected in 2025 and a Phase 3 trial for NVL-655 anticipated in early 2025.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 8:32 am

PFE

Pfizer announced positive results from its Phase 2 study of Ponsegromab, showing significant improvements in body weight, appetite, and muscle mass in cancer cachexia patients. The drug was safe and well-tolerated, with registration-enabling studies planned for 2025.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 8:19 am

PFE

Pfizer's BRAFTOVI + MEKTOVI demonstrates long-term efficacy in treating BRAF V600E-mutant metastatic non-small cell lung cancer, showing substantial antitumor activity and progression-free survival after three years.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 8:17 am

EL

Estée Lauder has advised its stockholders to reject TRC Capital's unsolicited mini-tender offer to purchase 1,500,000 shares at $83.65 per share, which is below the current market price. The company emphasizes that TRC's offer is not endorsed and highlights the risks associated with mini-tender offers.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 7:47 am

CODA

GOOG

GOOGL

RFIL

SMCI

VNCE

The S&P 500 and Nasdaq Composite recorded their best week of the year, with gains driven by stocks like Alphabet and Super Micro. The CNN Money Fear and Greed index moved to a 'Neutral' zone, indicating improved market sentiment. Investors are awaiting earnings from Coda Octopus, Vince Holding, and RF Industries.

Portfolio Pulse from Avi Kapoor

September 16, 2024 | 7:47 am

NTRA

Natera's Signatera test shows significant predictive power for overall survival in colorectal cancer patients, according to new data from the GALAXY study presented at ESMO. The test indicates a nearly 10x advantage in survival at 36 months based on ctDNA status and a 50% reduction in death risk for Signatera-positive patients treated with ACT.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 7:46 am

AAPL

DIS

NFLX

WBD

The 76th Primetime Emmy Awards highlighted the success of FX, a subsidiary of Disney, with 'Shōgun' and 'The Bear' winning multiple awards. Disney's FX led with 36 awards, surpassing its previous record. Netflix, HBO, and Apple TV+ also secured significant wins.

Portfolio Pulse from Ananya Gairola

September 16, 2024 | 7:24 am

EXEL

Exelixis, Inc. presented final Phase 3 CONTACT-02 study results at ESMO 2024, showing overall survival data for cabozantinib in combination with atezolizumab in metastatic prostate cancer patients.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 7:19 am